BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Inclusion Criteria: * 1\. Sign the written informed consent voluntarily; * 2\. Age ≥ 18, ≤ 75, male or female; * 3.Expected life ≥ 3 months * 4\. The physical condition score of the Eastern Tumor Cooperative Organization (ECOG) is 0-2; * 5.Biopsy sample or pathological wax slice test (within 1 year before signing the informed consent): target test positive * 6\. According to RECIST v1.1 solid tumor evaluation criteria, there is at least one measurable lesion; * 7\. Patients with recurrent/metastatic nasopharyngeal carcinoma who have received second-line or above system treatment failure in the past (Recurrence of nasopharyngeal carcinoma: nasopharyngeal carcinoma confirmed by pathology, after radical radiotherapy, the clinical tumor disappears completely, and after 6 months of treatment, local tumors with the same pathological type as the original tumor reappear; metastasis of nasopharyngeal carcinoma: tumor cells transfer from the primary site to distant organs through various ways, such as blood and lymph, and form tumor metastasis focus); * 8\. It is possible to establish a single blood collection or venous blood collection channel, and there is no other blood cell separation contraindication; * 9\. It has sufficient organ and bone marrow functions, as defined below routine blood test Neutrophil count (NEUT #) ≥ 1.0 × 10\^9/L Platelet count (PLT) ≥ 80 × 10\^9/L Hemoglobin concentration ≥ 90g/L Liver function: subjects without liver metastasis Aspartate aminotransferase (AST) ≤ 2.5 × Upper limit of normal value (ULN) Alanine aminotransferase (ALT) ≤ 2.5 × Upper limit of normal value (ULN) Total bilirubin (TBIL) ≤ 1.5 × ULN Liver function: subjects with liver metastasis Aspartate aminotransferase (AST) ≤ 5 × Upper limit of normal value (ULN) Alanine aminotransferase (ALT) ≤ 5 × Upper limit of normal value (ULN) Liver function: subjects with liver metastasis or Gilbert syndrome Total bilirubin (TBIL) ≤ 2 × ULN renal function Creatinine clearance rate (CCR) ≥ 50mL/min Coagulation function International normalized ratio (INR) ≤ 1.5 × ULN Activated partial thromboplastin event (APTT) ≤ 1.5 × ULN * 10\. Toxic side effects left by early anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.) ≤ Level 1 (CTCAE5.0); * 11\. During the study period and within 6 months after the last administration, subjects with fertility (male or female) must take effective medical contraceptive measures. Female subjects of childbearing age must have a pregnancy test within 72 hours before the first administration, and the result is negative. Exclusion Criteria: * 1\. Active central nervous system metastasis (except those that are stable after treatment); * 2\. HIV positive or HBsAg positive, HBV DNA copy number is positive (quantitative test ≥ 1000 cps/ml) or HCV antibody is positive and HCV RNA is positive; * 3\. Those who have mental or psychological diseases and cannot cooperate with the treatment and efficacy evaluation; * 4\. Subjects with severe autoimmune diseases and long-term application of immunosuppressants; * 5\. There is active infection or uncontrollable infection requiring systemic treatment within 14 days before signing the informed consent form; * 6\. Any unstable systemic disease (including but not limited to): Active infection (except local infection); Unstable angina pectoris; Cerebrovascular ischemia or cerebrovascular accident (within 6 months before screening); Myocardial infarction (within 6 months before screening); Congestive heart failure (New York Heart Association \[HYHA\] classification ≥ Ⅲ); Serious arrhythmia requiring drug treatment; Heart disease needs treatment or hypertension is out of control after treatment (blood pressure\>160mmHg/100mmHg); * 7\. Complicated with dysfunction of lung, brain, kidney and other important organs; * 8\. Subjects had undergone major surgery or severe trauma within 4 weeks before signing the informed consent form, or were expected to undergo major surgery during the study period. * 9\. Subjects received the last radiotherapy or anti-tumor treatment (chemotherapy, targeted therapy or immunotherapy) within 4 weeks before signing the informed consent form; * 10\. The subject currently suffers from or has suffered from other malignant tumors that cannot be cured within 3 years, except for cervical cancer or skin basal cell cancer, and other malignant tumors with a disease-free survival period of more than 5 years; * 11\. Have received T cells (including CAR-T and TCR-T) modified by chimeric antigen receptor within half a year before signing the informed consent form; * 12\. Graft versus host disease (GVHD) * 13\. Subjects who were receiving systemic steroid treatment before signing the informed consent form and who were judged by the investigator to need long-term use of systemic steroid treatment during the treatment period (except for inhalation or local use); And subjects treated with systemic steroids within 72 hours before cell reinfusion (except for inhalation or local use); * 14\. Serious allergy or allergy history * 15\. Subjects requiring anticoagulation treatment * 16\. Pregnant or lactating women, or have a pregnancy plan within six months (for both men and women); * 17\. The investigator believes that there are other reasons that cannot be included in the treatment